| [1] |
LHEUREUX S, GOURLEY C, VERGOTE I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177): 1240-1253.
|
| [2] |
SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J]. CA A Cancer J Clin, 2024, 74(1): 12-49.
|
| [3] |
GAITSKELL K, ROGOZIŃSKA E, PLATT S, et al. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer[J]. Cochrane Database Syst Rev, 2023, 4(4): CD007930.
|
| [4] |
LHEUREUX S, BRAUNSTEIN M, OZA A M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4): 280-304.
|
| [5] |
BU Y H, WU H, DENG R, et al. Therapeutic potential of SphK1 inhibitors based on abnormal expression of SphK1 in inflammatory immune related-diseases[J]. Front Pharmacol, 2021, 12: 733387.
|
| [6] |
KHOEI S G, SADEGHI H, SAMADI P, et al. Relationship between Sphk1/S1P and microRNAs in human cancers[J]. Biotechnol Appl Biochem, 2021, 68(2): 279-287.
|
| [7] |
HII L W, CHUNG F F, MAI C W, et al. Sphingosine kinase 1 regulates the survival of breast cancer stem cells and non-stem breast cancer cells by suppression of STAT1[J]. Cells, 2020, 9(4): 886.
|
| [8] |
NAGAHASHI M, MIYOSHI Y. Targeting sphingosine-1-phosphate signaling in breast cancer[J]. Int J Mol Sci, 2024, 25(6): 3354.
|
| [9] |
BAO J M, ZHI X, YUAN H Y, et al. Overexpression of SPHK1 associated with targeted therapy resistance in predicting poor prognosis in renal cell carcinoma[J]. Transl Cancer Res, 2023, 12(3): 572-584.
|
| [10] |
RIBONI L, ABDEL HADI L, NAVONE S E, et al. Sphingosine-1-phosphate in the tumor microenvironment: a signaling hub regulating cancer hallmarks[J]. Cells, 2020, 9(2): 337.
|
| [11] |
BEACH J A, ASPURIA P P, CHEON D J, et al. Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer[J]. Oncotarget, 2016, 7(4): 4167-4182.
|
| [12] |
HART P C, CHIYODA T, LIU X J, et al. SPHK1 is a novel target of metformin in ovarian cancer[J]. Mol Cancer Res, 2019, 17(4): 870-881.
|
| [13] |
ZHANG H W, WANG Q Y, ZHAO Q, et al. miR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1[J]. J Ovarian Res, 2013, 6(1): 84.
|
| [14] |
DAI L, LIU Y X, XIE L, et al. Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis[J]. Oncotarget, 2017, 8(43): 74947-74961.
|
| [15] |
RAMOS A, SADEGHI S, TABATABAEIAN H. Battling chemoresistance in cancer: root causes and strategies to uproot them[J]. Int J Mol Sci, 2021, 22(17): 9451.
|
| [16] |
ALKAFAAS S S, ELSALAHATY M I, ISMAIL D F, et al. The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target[J]. Cancer Cell Int, 2024, 24(1): 89.
|
| [17] |
LING Q, JI K, CHEN J, et al. Sphingosine kinase-1 regulates migration and invasion of gastric cancer cells via targeting the nuclear factor-κB signaling pathway[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2024, 44(11): 2163-2171.
|
| [18] |
MA Y F, XING X, KONG R R, et al. SphK1 promotes development of non-small cell lung cancer through activation of STAT3[J]. Int J Mol Med, 2020, 47(1): 374-386.
|
| [19] |
WANG S S, LIANG Y Y, CHANG W X, et al. Triple negative breast cancer depends on sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P)/sphingosine 1-phosphate receptor 3 (S1PR3)/Notch signaling for metastasis[J]. Med Sci Monit, 2018, 24: 1912-1923.
|
| [20] |
LIU D, LIU L L, LI H M, et al. Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K/AKT/PD-L1 axis[J]. Int Immunopharmacol, 2024, 143(Pt 2): 113361.
|
| [21] |
FANG Q, CHEN X, CAO F, et al. SPHK1 promotes HNSCC immune evasion by regulating the MMP1-PD-L1 axis[J]. Theranostics, 2024, 14(18): 7199-7218.
|
| [22] |
QIN Z J, TONG H, LI T H, et al. SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis[J]. Int J Mol Med, 2021, 48(5). DOI:10.3892/ijmm.2021.5037 .
doi: 10.3892/ijmm.2021.5037
|
| [23] |
KAO W H, LIAO L Z, CHEN Y, et al. SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade[J]. Cell Death Dis, 2024, 15(9): 678.
|
| [24] |
QIU J G, XU Q, PANAH T, et al. Reactive oxygen species mediate ovarian cancer development, platinum resistance, and angiogenesis via CXCL8 and GSK-3β/p70S6K1 axis[J]. Genes Dis, 2025, 12(2): 101378.
|
| [25] |
ZHU J W, CHARKHCHI P, AKBARI M R. Potential clinical utility of liquid biopsies in ovarian cancer[J]. Mol Cancer, 2022, 21(1): 114.
|
| [26] |
WANG C, LI Q, SONG K Q, et al. Nanoparticle co-delivery of carboplatin and PF543 restores platinum sensitivity in ovarian cancer models through inhibiting platinum-induced pro-survival pathway activation[J]. Nanoscale Adv, 2024, 6(16): 4082-4093.
|